Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#249 of 388

Raghuram Selvaraju

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2017No new ratings since Jul 2025

Analyst rating accuracy & track record

Raghuram Selvaraju is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 369 of their stock calls across 57 companies. Their picks beat their sector 37% of the time over the next 12 months, and their price targets were reached 11% of the time within a year.

Win % vs sector
37%
PT Hit % (12mo)
11%
Avg sector-excess
−10.0%
Scored calls
369
Tickers
57
Tier
Established

Track record

Quantellect has scored 369 of Raghuram Selvaraju's stock calls across 57 companies, dating back to 2017. Their rated stocks beat their own sector 37% of the time over the next 12 months. On a typical call, a Selvaraju pick returned −10.0% more than its sector over the following year.

Of the scored calls, 369 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ABEOAbeona Therapeutics Inc
Buy$20.00Jul 2025−17.6%Miss
INVAInnoviva Inc
Buy$40.00Jul 2025−12.0%Miss
ABEOAbeona Therapeutics Inc
Buy$20.00Jul 2025−2.3%Miss
URGNUroGen Pharma Ltd
Buy$50.00Jul 2025+154.0%Miss
GANXGain Therapeutics Inc
Buy$8.00Jul 2025−9.0%Miss
PCSAProcessa Pharmaceuticals Inc
Buy$2.00Jun 2025−79.2%Hit
AARDAardvark Therapeutics, Inc. Common Stock
Buy$40.00Jun 2025−75.1%Miss
ACRSAclaris Therapeutics Inc
Buy$16.00Jun 2025+197.3%Miss
SEPNSepterna, Inc. Common Stock
Buy$26.00Jun 2025+226.2%Hit
BTAIBioXcel Therapeutics Inc
Buy$8.00Jun 2025−42.4%Hit
COCPCocrystal Pharma Inc
Buy$6.00Jun 2025−51.3%Miss
AQSTAquestive Therapeutics Inc
Buy$10.00Jun 2025+15.7%Miss
URGNUroGen Pharma Ltd
Buy$50.00Jun 2025+125.2%Miss
OMEROmeros Corporation
Buy$9.00Jun 2025+167.2%Hit
ANVSAnnovis Bio Inc
Buy$12.00Jun 2025−54.5%Miss
FENCFennec Pharmaceuticals Inc
Buy$13.00May 2025+3.8%Miss
GANXGain Therapeutics Inc
Buy$8.00May 2025−28.1%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$28.00May 2025−34.4%Miss
ASRTAssertio Therapeutics Inc
Buy$3.50May 2025+116.1%Miss
ACOGAlpha Cognition Inc
Buy$20.00May 2025−52.9%Miss
AQSTAquestive Therapeutics Inc
Buy$10.00May 2025+64.2%Miss
ACRSAclaris Therapeutics Inc
Buy$16.00May 2025+280.2%Miss
URGNUroGen Pharma Ltd
Buy$55.00May 2025+197.5%Miss
VNDAVanda Pharmaceuticals Inc
Buy$20.00May 2025+41.6%Miss
RGENRepligen Corporation
Buy$180.00May 2025−13.8%Miss
ABEOAbeona Therapeutics Inc
Buy$20.00Apr 2025−29.3%Miss
URGNUroGen Pharma Ltd
Buy$55.00Apr 2025+119.0%Miss
BCPCBalchem Corporation
Buy$180.00Apr 2025−11.3%Hit
SLNOSoleno Therapeutics Inc
Buy$100.00Apr 2025−59.5%Miss
PYPDPolyPid
Buy$11.00Apr 2025+53.7%Miss
MBOTMicrobot Medical Inc
Buy$9.00Apr 2025+6.6%Miss
GMABGenmab AS
Buy$37.00Apr 2025+44.3%Miss
NAGENiagen Bioscience, Inc.
Buy$11.00Apr 2025−33.6%Hit
AVXLAnavex Life Sciences Corp
Buy$42.00Apr 2025−71.7%Miss
AQSTAquestive Therapeutics Inc
Buy$10.00Apr 2025+39.5%Miss
ACOGAlpha Cognition Inc
Buy$20.00Apr 2025+13.1%Miss
EBSEmergent Biosolutions Inc
Buy$15.00Apr 2025+57.9%Miss
VNDAVanda Pharmaceuticals Inc
Buy$20.00Apr 2025+52.6%Miss
ACOGAlpha Cognition Inc
Buy$20.00Mar 2025+9.1%Miss
NAGENiagen Bioscience, Inc.
Buy$11.00Mar 2025−39.9%Hit
SLNOSoleno Therapeutics Inc
Buy$100.00Mar 2025−68.2%Miss
AVXLAnavex Life Sciences Corp
Buy$42.00Mar 2025−65.8%Miss
ENLVEnlivex Therapeutics Ltd
Buy$7.00Mar 2025−0.5%Miss
RMTIRockwell Medical Inc
Buy$3.00Mar 2025−15.6%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$28.00Mar 2025−28.5%Miss
EBSEmergent Biosolutions Inc
Buy$15.00Mar 2025+40.4%Miss
ASRTAssertio Therapeutics Inc
Buy$3.50Mar 2025+27.1%Miss
ACOGAlpha Cognition Inc
Buy$20.00Mar 2025−1.0%Miss
ENTXEntera Bio Ltd
Buy$10.00Mar 2025−33.2%Miss
GANXGain Therapeutics Inc
Buy$8.00Mar 2025+6.4%Miss
Go to

Raghuram Selvaraju: analyst track record FAQ

Is Raghuram Selvaraju a good stock analyst?

Yes, by track record. Raghuram Selvaraju ranks number 249 of 388 of the analysts Quantellect scores, with a Q Score of 20 out of 100. Past results do not guarantee future ones.

What is Raghuram Selvaraju's win rate?

Raghuram Selvaraju's win rate is 37%. Across 369 scored calls, their rated stocks beat their sector 37% of the time over the next 12 months. On a typical call they returned −10.0% more than the sector.

What stocks and sectors does Raghuram Selvaraju cover?

Raghuram Selvaraju covers 57 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Raghuram Selvaraju's price targets accurate?

Raghuram Selvaraju's price targets are reached within 12 months 11% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Raghuram Selvaraju's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Raghuram Selvaraju rank among Wall Street analysts?

Raghuram Selvaraju ranks number 249 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.